China’s Oppo doubles down on foldable smartphones as potential Apple entry looms


Chinese smartphone maker Oppo is mounting a fresh challenge in the foldable handset market after launching the latest product in its Find N series, as the industry faces rising memory prices and anticipation builds around Apple’s foldable iPhone.

Find N6, launched globally on Tuesday, featured upgraded hinge technology designed to make the crease on the foldable screen “virtually imperceptible”, according to the company.

“While foldables offer the advantage of a larger display, the crease has remained one of the primary concerns for users,” said Pete Lau, senior vice-president and chief product officer at Oppo. “It’s a challenge Oppo has sought to solve ever since the original Find N.”

The handset has a thickness of just 8.93mm (0.35 inches) when folded and weighs 225 grams (7.9 ounces). It runs on Qualcomm’s Snapdragon 8 Elite Gen 5 mobile platform, supporting artificial intelligence capabilities and multitasking performance.

Oppo’s latest push into the premium segment comes as smartphone makers grapple with surging component costs amid a memory shortage. The memory crunch has threatened to squeeze profit margins and forced companies to raise prices.

Find N6 is 8.93mm thick when folded and weighs 225 grams. Photo: Handout
Find N6 is 8.93mm thick when folded and weighs 225 grams. Photo: Handout

Last week, Oppo announced price increases of 300 yuan (US$44) to 500 yuan on some handsets “in the face of rising costs for multiple key smartphone components including high-speed memory hardware”. The new prices took effect on Monday.

  • Related Posts

    Tencent’s Pony Ma to open museum in Shenzhen, led by Tai Kwun’s former head of art Pi Li

    Details of the Shenzhen museum being built by Pony Ma Huateng, co-founder and CEO of internet giant Tencent Holdings, were unveiled on March 17 after months of speculation. In a…

    Continue reading
    US reshoring drive casts shadow over China’s contract drug makers: analyst

    Chinese contract drug makers – including WuXi AppTec, WuXi Biologics and WuXi XDC – face a less certain long-term revenue outlook as US pharmaceutical companies bring production in-house and reconfigure…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *